Eisai Co Ltd's new patent offers a promising therapeutic agent for treating fatty liver diseases, including NAFLD and NASH, enhancing patient care and management.

Miki Sogi, an analyst from Bernstein, maintained the Buy rating on Eisai Co (ESALF – Research Report). The associated price target is ...

Despite its marketing approval, Leqembi’s cost effectiveness falls short of NICE’s standards to justify wide range use in the ...

In a decision contrary to its European counterpart, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai and Biogen's new Leqembi drug, ...

Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently ...

Modeling suggests monthly maintenance dosing will keep biomarkers flat. Several talks showed how fluid biomarkers rebound after patients stop taking the drug. Likewise, cognitive decline returned to ...

Lecanemab – a drug shown to slow the progression of Alzheimer’s disease – has as been approved for use in the UK, but will ...

In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* ...

Eisai, which serves as the lead for the drug’s development ... emeritus professor at Durham University and chief executive officer and co-founder of Nevrargenics, a Durham spinout company developing ...

The firms leading the latest list mostly retained their positions over the past year despite some large moves in revenue. But ...

Eisai Company Limited (4523.T), a leading pharmaceutical company, reported a steady increase in revenue from its pharmaceutical business, driven by the growth of its key drugs including LEQEMBI ...